Skip to content

Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial

Achondroplasia (ACH) is the most common form of skeletal abnormality. Currently, there is no agreement about the best way to treat ACH. Current treatment options, aimed at preventing or treating complications of ACH, may be painful and are not guaranteed to be effective.

The purpose of this study is to collect data on the growth pattern of children with ACH.

null

Conditions de participation

  • Sexe:

    Female, Male

  • Âges admissibles:

    2 to 10

Critères de participation

Inclusion Criteria:
Aged 2.5 to 10 years
Diagnosed with ACH
Ambulatory and able to stand without assistance
Exclusion Criteria:
Girls who have started having periods
Disorders such as: hyperthyroidism; abnormal thyroid levels; insulin requiring diabetes; autoimmune inflammatory disease; inflammatory bowel disease or autonomic neuropathy.
A low hemoglobin
Insufficient liver or kidney function.
Clinically significant cardiac or vascular disease
Previous treatment with growth hormone / factor or anabolic steriods
Regular treatment with oral or inhaled steroids
Previous investigational product use for ACH
Previous limb-lengthening surgery.

Lieu de l'étude

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Lee-Ann Carroll

[email protected]
7804924902
Étude parrainée par
University of Alberta
Participants recherchés
Plus d'informations
ID de l'étude: Pro00097372